Department of Pharmacology, Faculty of Pharmaceutical Sciences, Tohoku Medical and Pharmaceutical University, 4-4-1 Komatsushima, Aoba-ku, Sendai 981-8558, Japan.
Consumer Healthcare Products Development, Zeria Pharmaceutical Co., Ltd., 10-11 Nihonbashi, Kobuna-cho, Chuo-ku, Tokyo 103-8351, Japan.
J Pharmacol Sci. 2018 Aug;137(4):403-406. doi: 10.1016/j.jphs.2018.03.003. Epub 2018 Mar 23.
We examined whether chondroitin sulfate (CS), a compound used to treat osteoarthritis and joint pain, is effective against partial sciatic nerve ligation (PSNL)-induced neuropathic pain. Repeated oral administration of CS (300 mg/kg, b.i.d. for 20 days) resulted in inhibition of tactile allodynia observed 21 days after PSNL. On day 21, phosphorylation of spinal p38 mitogen-activated protein kinase (MAPK) was attenuated by CS. CS also inhibited c-Fos upregulation in ipsilateral deep dorsal horn (laminae III-IV) neurons, which receive Aβ-fiber afferent inputs. These findings suggest that CS attenuates PSNL-induced tactile allodynia by inhibiting spinal p38 MAPK phosphorylation and Aβ-fiber activation.
我们研究了硫酸软骨素(CS)——一种用于治疗骨关节炎和关节疼痛的化合物——是否对坐骨神经部分结扎(PSNL)诱导的神经性疼痛有效。CS 的重复口服给药(300mg/kg,bid 给药 20 天)可抑制 PSNL 后 21 天观察到的触觉过敏。在第 21 天,CS 减弱了脊髓 p38 丝裂原活化蛋白激酶(MAPK)的磷酸化。CS 还抑制了同侧背角(III-IV 层)神经元中 c-Fos 的上调,这些神经元接收 Aβ 纤维传入输入。这些发现表明,CS 通过抑制脊髓 p38 MAPK 磷酸化和 Aβ 纤维激活来减轻 PSNL 诱导的触觉过敏。